Lipocine Inc., a biopharmaceutical company focused on oral delivery of therapeutics, announced that its licensing partner, Verity Pharma, has filed a New Drug Submission (NDS) for TLANDO® in Canada. TLANDO is the first and only oral testosterone replacement therapy $(TRT)$ approved by the U.S. FDA that does not require dose titration. This submission represents a significant step towards making TLANDO available in the Canadian market, which sees over 700,000 TRT prescriptions written annually. If approved, TLANDO could capture a substantial market share due to its unique oral administration and the limited promotional activities for current TRTs. Lipocine and Verity Pharma entered an exclusive licensing agreement in January 2024 for commercial rights in the United States and Canada.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。